Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

[Purpose] Relebactam is a novel β-lactamase inhibitor, which, when combined with imipenem/cilastatin, is active against both class A and class C β-lactamases. To evaluate in vitro antimicrobial activity of imipenem/relebactam against a collection of recent clinical isolates of carbapenem-non-suscept...

Full description

Bibliographic Details
Authors: Delgado-Valverde, Mercedes, Portillo-Calderón, Inés, Alcalde-Rico, Manuel, Conejo, M. Carmen, Hidalgo-Díaz, Carmen, Toro Esperón, Carlos del, Pascual, Álvaro
Format: article
Status:Published version
Publication Date:2024
Country:España
Institution:Consejo Superior de Investigaciones Científicas (CSIC)
Repository:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/359839
Online Access:http://hdl.handle.net/10261/359839
https://api.elsevier.com/content/abstract/scopus_id/85180895240
Access Level:Open access
Keyword:Imipenem/relebactam
K. pneumoniae
P. aeruginosa
Carbapenem-resistant
Description
Summary:[Purpose] Relebactam is a novel β-lactamase inhibitor, which, when combined with imipenem/cilastatin, is active against both class A and class C β-lactamases. To evaluate in vitro antimicrobial activity of imipenem/relebactam against a collection of recent clinical isolates of carbapenem-non-susceptible P. aeruginosa and K. pneumoniae ST258 and ST512 KPC producers belonging to different lineages from hospitals in Southern Spain.

Similar Items